Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IBRX
#1037
ImmunityBio, Inc. Common Stock
7.5
8
USD
+3.84%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+3.84%
Monthly Change
-11.03%
6 month change
+201.99%
Year Change
+153.51%
Previous Close
7.3
0
Open
7.6
7
Bid
Ask
Low
7.5
8
High
7.6
8
Volume
768
Markets
US Stock Market
Healthcare
IBRX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
109.34 M
397.91 M
435.84 M
673.95 M
853.44 M
1.03 B
—
Valuation ratios
Enterprise value
—
2.24 B
1.96 B
4.15 B
2.37 B
2.31 B
10.68 B
Price to earnings ratio
—
-6.83
-4.59
-4.56
-4.13
-5.21
-22.26
Price to sales ratio
—
2 533.77
7 948.02
4 284.97
121.61
16.08
155.25
Price to cash flow ratio
—
-8.62
-5.65
-7.27
-4.58
-5.97
-24.09
Price to book ratio
—
-9.77
-4.26
-4.54
-3.67
-3.64
-6.31
Enterprise value to EBITDA ratio
—
-7.08
-5.92
-9.5
-6.25
25.23
-301.82
Profitability ratios
Return on assets %
-0.61
-0.74
-1.15
-1.16
-1.08
-0.7
-0.91
Return on equity %
-0.79
1.42
0.93
1
0.85
0.7
0.63
Return on invested capital %
-406.35
-499.19
-255.38
-327.6
-630.3
-482.51
-477.16
Gross margin %
100
100
100
100
100
99.34
397.58
Operating margin %
-82.55 K
-35.36 K
-146.37 K
-58.24 K
-2 334.23
-226
-1 002.3
EBITDA margin %
-74.31 K
-33.84 K
-138.77 K
-55.26 K
-2 215.18
68.17
308.16
Net margin %
-83.23 K
-37.13 K
-173.57 K
-93.76 K
-2 804.77
-310.18
-1 506.74
Liquidity ratios
Quick ratio
—
—
—
—
3.21
5.08
16.76
Current ratio
3.06
0.91
0.28
5.05
3.36
5.1
17.19
Inventory turnover
—
—
—
—
0
0.16
0.15
Asset turnover
0
0
0
0
0.03
0.26
0.27
Solvency ratios
Debt to assets ratio
—
—
-0.04
1.75
0.85
0.73
3.4
Debt to equity ratio
—
—
0.03
-1.5
-0.67
-0.73
-2.6
Long term debt to total assets ratio
—
—
-0.18
1.66
0.74
0.65
2.99
Long term debt to total equity ratio
—
—
0.14
-1.43
-0.58
-0.65
-2.29
Per share metrics
Operating cash flow per share
—
-0.71
-0.84
-0.72
-0.56
-0.33
-0.34
EBIT per share
—
-0.85
-0.88
-0.71
-0.49
-0.28
-0.28
EBITDA per share
—
-0.81
-0.83
-0.68
-0.47
0.08
0.1
Total debt per share
—
—
-0.03
1.73
0.47
0.4
1.56
Cash per share
—
0.81
0.27
0.52
0.21
0.26
0.78
Net current asset value per share
—
0.86
0.35
0.58
0.26
0.34
1.05
Tangible book value per share
—
-0.63
-1.17
-1.19
-0.72
-0.56
-2.5
Working capital per share
—
-0.09
-0.9
0.46
0.19
0.28
0.81
Book value per share
—
-0.62
-1.12
-1.15
-0.7
-0.54
-2.43
News
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
Why Is ImmunityBio Stock Rallying Thursday? - ImmunityBio (NASDAQ:IBRX)
ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold (NASDAQ:IBRX)
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - ImmunityBio (NASDAQ:IBRX)
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26% - TipRanks.com
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
ImmunityBio Crashes On FDA Warning Over Anktiva Claims - ImmunityBio (NASDAQ:IBRX)
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion